Pricing Log in Create free account

Clovis Oncology, Inc. (CLVSQ) vs Lipocine Inc. (LPCN)

Clovis Oncology, Inc. and Lipocine Inc. are both Biotechnology companies. Clovis Oncology, Inc. and Lipocine Inc. are of similar size ($14.2M and $13.9M). Clovis Oncology, Inc. grew revenue faster over the last twelve months: −14.8% against −63.5%. Clovis Oncology, Inc. has the higher net margin (−189.4% vs −755.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Clovis Oncology, Inc. leads on 10 and Lipocine Inc. on 6.

Valuation

Metric CLVSQ LPCN Biotechnology median
P/E n/m n/m 8.50
P/S 0.10 7.75 9.71
P/B n/m 0.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.64 0.64
EV/Sales 3.08 (5.21) 9.21
Earnings yield (2,033.33%) (126.35%) (33.15%)
Free cash flow yield (1,412.40%) (92.84%) (25.50%)

Profitability

Metric CLVSQ LPCN Biotechnology median
Gross margin 72.21% 100.00% 65.16%
Operating margin (155.38%) (800.80%) 0.00%
Net margin (189.37%) (755.11%) 0.00%
Free cash flow margin (132.19%) (713.02%) 0.00%
Return on equity 78.31% (60.94%) (56.36%)
Return on assets (58.94%) (55.89%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLVSQ LPCN Biotechnology median
Revenue growth (TTM) (14.78%) (63.48%) 6.02%
EPS growth (last fiscal year) 47.72% (93,988.89%) 30.26%
Revenue growth, 5-year CAGR 352.98% 64.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLVSQ LPCN Biotechnology median
Debt to equity (1.05) 0.00 0.00
Current ratio 0.14 11.48 4.72
Net debt to EBITDA (2.16) 1.42 0.96

Dividend

Metric CLVSQ LPCN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLVSQ LPCN Biotechnology median
Market cap 14.23m 13.85m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack